Description du projet
Une plateforme innovante simplifie la manière dont les poules nous aident à combattre les maladies
Les immunoglobulines (ou anticorps) sont des molécules produites par nos globules blancs; elles sont capables de reconnaître les «envahisseurs», et d’aider à les détruire. Les êtres humains produisent cinq classes différentes d’immunoglobulines; l’une d’entre-elles a un fonctionnement similaire à l’anticorps spécial IgY, notamment produit par les poulets. L’anticorps IgY circulant s’accumule dans le jaune des œufs de poule. Ce processus est particulièrement pratique, car les scientifiques sont en mesure d’immuniser les poulets contre plusieurs agents pathogènes différents, notamment ceux capables d’infecter l’être humain, puis de purifier les anticorps IgY à partir du jaune d’œuf, sans avoir à recourir à la production complexe d’anticorps monoclonaux dérivés de l’être humain. Actuellement, le projet PureIgY financé par l’UE développe une méthode plus simple et plus abordable pour isoler l’anticorps IgY de manière à augmenter considérablement le rendement. L’équipe se focalise sur l’utilisation d’une plateforme innovante permettant de développer rapidement des thérapies contre les agents pathogènes résistants aux antimicrobiens.
Objectif
The increased occurrence of antibiotic-resistant pathogens is a critical concern corresponding to economic and societal challenges of high priority. Antimicrobial resistance (AMR) is responsible for 33,000 deaths per year, while bringing €1.5 billion per year in healthcare costs and productivity losses to the EU. Current solutions (biopharmaceuticals) are highly expensive and very few tackle the AMR scenario. Therefore, new approaches to tackling AMR focusing on low cost and relatively low time-to-market therapeutics must be pursued. Immunoglobulin Y (IgY) present in hen’s egg yolk is a potential alternative to the previously described biotherapeutics, and can be obtained in higher amounts from a renewable and non-invasive matrix. However, given the complex nature of egg yolk, the current purification technologies are multi-step and mainly based on chromatography, being highly expensive and leading to low yields. In the ERC Starting Grant (IgYPurTech) I proposed the use of aqueous biphasic systems (ABS) as IgY separation/purification platforms (from commercial and non-hyperimmune eggs since no therapeutic action was defined in the proposal). Although promising results have been obtained with ABS, during the IgYPurTech framework an additional and more cost-effective process to purify IgY was developed. It is not based on the selective extraction of antibodies for one of the phases in ABS, but on two steps of induced precipitation with appropriate salts and biopolymers. This innovative purification platform enables to produce high-quality IgY in higher amounts and at a significantly lower cost than other currently commercialized biotherapeutics. In this PoC Action – PureIgY – it is aimed to scale-up the developed purification technology, to address the biological features of specific IgY to tackle the AMR critical scenario, to work on the business plan development and business development, and to create an early-stage drug development start-up.
Champ scientifique
Programme(s)
Régime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
3810-193 Aveiro
Portugal